Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
News A vote of no confidence in UK's pricing system The new PPRS is not good news for all pharma companies, concludes industry audience
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
